Brought to you by 
Rhei to sell Flamel's aspirin product in Asia
23 Jul 2019
Executive Summary
Flamel Technologies SA (delivery of small molecules and proteins) licensed Rhei Pharmaceuticals, a company that in-licenses, develops, and sells drugs in the Chinese market, exclusive rights to sell the controlled-release aspirin Asacard in the Greater China territory including China, Taiwan, Hong Kong, and Macau.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Controlled Release
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Rhei to sell Flamel's aspirin product in Asia
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice